About
Arthramid

PAAG was used as a tissue filler in facial corrective surgery and breast augmentation with reportedly very good results.

Arthramid was developed as a treatment for joint lameness in horses, showing significant improvements in managing osteoarthritis

Tnibar et al tests Arthramid in an experimental OA model in goats and shows an improvement in joint capsule elasticity and ability to halt the progression of the disease seen on MRI.

Janssen et al publishes an article on the use of Arthramid to treat distal interphalangeal joint lameness in 12 horses unresponsive to other therapies.

Arthramid becomes recognized for veterinary use to improve comfort in cases of degenerative joint diseases like osteoarthritis.

Tnibar et al publishes international multi-centre prospective study with long-term follow-up on the use of Arthramid in horses with OA.

This study demonstrates that Arthramid is a safe and effective treatment for osteoarthritis and joint lameness in horses and provides clinical evidence of its potential as a pioneering treatment for this debilitating disease.

Multiple clinical studies, presentations and conference proceedings confirm the long-lasting and superior results of Arthramid compared to conventional treatments and show significant improvements in joint function and reduction in pain and inflammation.

Arthramid is approved in New Zealand and Australia as a Veterinary Medicinal Product after satisfying local regulators in clinical efficacy, safety, chemistry, manufacturing, and toxicology modules.

Studies validate the safety of Arthramid, showing no cytotoxic or neurotoxic effects and it was proven to be a stable and effective treatment for long-term management of osteoarthritis in horses.

de Clifford and Lowe et al publish a double-blinded positive control study comparing the efficacy of 2.5% polyacrylamide hydrogel (PAAG) against triamcinolone acetonide (TA) and sodium hyaluronate (HA) in managing middle carpal joint lameness in racing Thoroughbreds.

The study confirmed PAAG’s superior efficacy and safety profile

Contura becomes an educational partner for the AAEP, Tnibar publishes a review article on 2.5% PAAG, and further research focuses on understanding the precise therapeutic action of PAAG on the synovium, which is recognized as a critical factor in the pain of osteoarthritis.

This leads to improved treatment protocols and a better understanding of outcomes for equine patients

Lowe et al publishes histology and safety study confirming that Arthramid induces a typical low-level foreign body response that is predominantly macrophage-driven with no toxic effects or evidence of fibrosis or mineralization. Integration of the gel is evident by 14 days, with no free gel remaining in the joint cavity.

Ongoing research, including with Colorado State University, continues to explore long-term safety in racing and performance horses, and a better understanding of the mechanism of action of PAAG in veterinary medicine, including investigating its use in canine OA and refining treatment protocols for optimal results.